TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TG THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$53.30−0.67 (-1.24%)
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
TG THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $606.93M | $313.73M | $92.01M | $2.63M | $6.54M | $0 | – | 98.5% | +93.5% |
| License [Member] | $9.36M | $15.28M | $141.66M | $152.00K | $152.00K | $152.00K | $152.00K | 1.5% | -38.7% |
| Royalty [Member] | $5.62M | $801.00K | $0 | $0 | – | – | – | 0.9% | +601.0% |
| Other Revenue [Member] | $3.59M | $1.82M | $1.50M | $0 | $0 | – | – | 0.6% | +97.0% |
| License Revenue [Member] | $152.00K | $152.00K | $140.15M | $152.00K | $152.00K | – | – | 0.0% | 0.0% |
| Milestone [Member] | $0 | $12.50M | $0 | $0 | – | – | – | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Tg Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.